I don't see too many of the big guys- the Novartis of the world say being interested in a non novel repurposed drug that has so far shown it's comparatively inferior to other proteinuria lowering drugs when they are added to arb (E.G. SGLT2 inhibitor). The big players want novel stuff. But you never know maybe DXB will manage to snare another advanz type player for US after the result next week. FOMO? I doubt it somehow.
I don't see too many of the big guys- the Novartis of the world...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
0.005(1.49%) |
Mkt cap ! $186.8M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 35.0¢ | 33.5¢ | $1.543M | 4.480M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 160288 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 340963 | 8 |
View Market Depth
| Last trade - 16.10pm 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
34.5¢ |
Change
0.005 ( 1.47 %) |
||||
| Open | High | Low | Volume | ||
| 33.5¢ | 35.0¢ | 33.5¢ | 2483392 | ||
| Last updated 15.58pm 16/05/2024 ? | |||||
| DXB (ASX) Chart |